What is KESIMPTA®?

Something new for relapsing MS

Header

KESIMPTA can impact relapsing
MS—in more ways than one

Whether you're deciding on your first treatment or thinking about making a switch, KESIMPTA may be able to provide something new.
KESIMPTA went head-to-head against AUBAGIO® in 2 studies.

Wondering if KESIMPTA may be right for you?
Keep exploring to:

Line

How KESIMPTA works

Here’s what goes on with relapsing MS:

The immune system uses certain cells, like B cells, to help fight infections. These cells can become activated in the lymph nodes—the communication hub for the immune system. 

But there’s a miscommunication that happens in relapsing MS. Instead of protecting the immune system, these cells mistakenly attack the body’s myelin—the fatty, protective covering of the nerves in the brain and spinal cord.

Here’s what KESIMPTA does:
Target icon
Although it's not known exactly how KESIMPTA works in relapsing MS, it's thought to travel specifically to the lymph nodes based on the way it's taken. From there, it's thought to reduce the number of B cells that are thought to play a role in relapsing MS.
This targeted approach to the lymph nodes is thought to limit the impact on other B cells your body needs to maintain immune function.
Line
MS=multiple sclerosis.
SENSOREADY is a registered trademark of Novartis AG.
AUBAGIO (teriflunomide), a leading oral relapsing MS treatment, is a registered trademark of Sanofi and Genzyme.